Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Studies examining the efficacy, safety and mechanisms of action of agents for the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed, with an emphasis on newer agents such as the long acting stimulants and atomoxetine. Recent studies of medications are characterized by large, rigorously diagnosed samples of children, adolescents and adults with ADHD, use of standardized rating scales and extensive safety data. These studies confirm a robust treatment effect for the Food and Drug Administration approved agents ranging from 0.7 to 1.5. The most common short term side effects to the most commonly used agents include insomnia, loss of appetite, and headaches. Despite public controversy and labeling changes to warn of extremely rare cardiovascular and psychiatric side effects, the evidence does not support the hypothesis that medication for ADHD increases risk for sudden death, mania or psychosis. A wide variety of neuroimaging techniques including electrocephalogram (EEG) power, event related potentials (ERP), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are beginning to examine the mechanisms of action of medications for ADHD, and implicating the catecholamines and prefrontal and anterior cingulate cortices as prime sites of actions for these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerability, response rates, and adverse-event profiles (Spencer et al., 1996; Efron et al., 1997; Pliszka, 2007; Newcorn et al., 2008; Victor et al., 2009; Wilens et al., 2011; Hodgkins et al., 2012).”
From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Pliszka, 2007
In the citing paper
“pharmacological treatment has limitations including unfavorable side effects for some patients [8]”
From Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD (2018) · cites this paper as [8]
Citations
Cites
ADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
ADHD and the Nature of Self-Control
Hinshaw, S. P. (1998) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-199806000-00010 · Cited by 1,194
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE
Bradley, C. (1937) · American Journal of Psychiatry · doi:10.1176/ajp.94.3.577 · Cited by 1,035
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885 · cited 2×
“transporters in the striatum (Volkow et al., 1998).”
BackgroundInfluentialBush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., Rosen, B. R., & Biederman, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00083-9 · Cited by 866 · cited 2×
“…comparisons of ADHD children to controls during fMRI have shown differences in fronto-striatal activity (Bush, Valera, & Seidman, 2005), particularly in the right prefrontal cortex (Rubia, Smith, Brammer, Toone, & Taylor, 2005) and anterior cingulate (Bush et al., 1999; Pliszka et al., 2006b).”
BackgroundVaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 1×
“Initially, Vaidya et al. (1998) showed that MPH, relative to placebo, increased frontal activation in both children with ADHD and controls.”
BackgroundPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 2×
“were found in 161 studies encompassing 5 preschool, 140 school age, 7 adolescent and 9 adult RCTs (Spencer et al., 1996).”
BackgroundBarry, R. J., Clarke, A. R., & Johnstone, S. J. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00362-0 · Cited by 819 · cited 1×
“Healthy controls produce a larger P300 wave to the oddball tones than to the common tones, but this difference is markedly reduced in children with ADHD (Barry et al., 2003).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · cited 7×
“Thus it is tempting to conclude that MPH increases the allocation of mental resources to a task, but Springer further studies have not borne this out.”
BackgroundInfluentialVolkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y.-S., Gatley, S. J., Gifford, A., & Franceschi, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0001.2001 · Cited by 770 · cited 2×
“Nonetheless, Volkow et al. (2001) established that MPH acutely increases the amount of dopamine in the synaptic cleft.”
BackgroundMethodBush, G., Valera, E. M., & Seidman, L. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.034 · Cited by 714 · cited 1×
“Using primarily measures of inhibitory control, comparisons of ADHD children to controls during fMRI have shown differences in fronto-striatal activity ( Bush, Valera, & Seidman, 2005 ), particularly in the right prefrontal cortex (Rubia, Smith, Brammer, Toone, & Taylor, 2005) and anterior cingulate (Bush et al., 1999…”
BackgroundReducing Antibiotic Use in Children: A Randomized Trial in 12 Practices
Finkelstein, J. A., Davis, R. L., Dowell, S. F., Metlay, J. P., Soumerai, S. B., Rifas-Shiman, S. L., Higham, M., Miller, Z., Miroshnik, I., Pedan, A., et al. (2001) · Pediatrics · doi:10.1542/peds.108.1.1 · Cited by 674
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588 · cited 2×
“The closely related alpha-2A agonist guanfacine was superior to placebo in reducing ADHD symptoms in children with comorbid ADHD and tics (Scahill et al., 2001), although it did not improve executive functioning in healthy adult volunteers (Muller et al., 2005).”
BackgroundRubia, K., Smith, A. B., Brammer, M. J., Toone, B., & Taylor, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1067 · Cited by 537
Treatment of ADHD in children with tics: A randomized controlled trial
The Tourette’s Syndrome Study Group (2002) · Neurology · doi:10.1212/wnl.58.4.527 · Cited by 504
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Thigpen, N. N., & Keil, A. (2017) · Reference Module in Neuroscience and Biobehavioral Psychology · doi:10.1016/b978-0-12-809324-5.02456-1 · Cited by 490
Event-related-potential (ERP) reflections of mental resource̊s: a review and synthesis
Kok, A. (1997) · Biological Psychology · doi:10.1016/s0301-0511(96)05221-0 · Cited by 447 · cited 2×
“The P300, which in these tasks is most prominent over the parietal areas, possibly reflects activity related to evaluation of the stimuli but may also represent the amount of mental capacity that is invested in the task (Kok, 1997).”
BackgroundPLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Self-citationBarry, R. J., Johnstone, S. J., & Clarke, A. R. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00363-2 · Cited by 434 · cited 1×
“Healthy controls produce a larger P300 wave to the oddball tones than to the common tones, but this difference is markedly reduced in children with ADHD (Barry et al., 2003).”
BackgroundEndocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
CORRELL, C. U., & CARLSON, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 403 · cited 2×
“Second generation antipsychotics should be used with caution, however, as children exposed to them chronically are at long term risk of weight gain, diabetes, and metabolic syndrome (Correll & Carlson, 2006).”
BackgroundPliszka, S. R., Liotti, M., & Woldorff, M. G. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00890-8 · Cited by 402
Self-citationMTA Cooperative Group (2004) · PEDIATRICS · doi:10.1542/peds.113.4.762 · Cited by 384
Volkow, N. D., Wang, G.-J., Fowler, J. S., & Ding, Y.-S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.006 · Cited by 368 · cited 2×
“carbon-11 to determine its distribution in the brain (Volkow et al., 2005).”
BackgroundKok, A. (1986) · Biological Psychology · doi:10.1016/0301-0511(86)90087-6 · Cited by 357
Klein, R. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240023003 · Cited by 349
Bupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity
CONNERS, C. K., CASAT, C. D., GUALTIERI, C. T., WELLER, E., READER, M., REISS, A., WELLER, R. A., KHAYRALLAH, M., & ASCHER, J. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00018 · Cited by 342 · cited 1×
“Bupropion is an antidepressant with effects primarily on the norepinephrine and dopamine systems that also shows modest efficacy in the treatment of ADHD (Conners et al., 1996).”
BackgroundEffects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335 · cited 1×
“The efficacy of second generation antipsychotic monotherapy in treating aggression is increasingly well established by controlled trials (Snyder et al., 2002).”
BackgroundCONNOR, D. F., GLATT, S. J., LOPEZ, I. D., JACKSON, D., & MELLONI, R. H. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00004 · Cited by 333
Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up
SWANSON, J. M., ELLIOTT, G. R., GREENHILL, L. L., WIGAL, T., ARNOLD, L. E., VITIELLO, B., HECHTMAN, L., EPSTEIN, J. N., PELHAM, W. E., ABIKOFF, H. B., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180686d7e · Cited by 323
Effect of Stimulant Medication on Children with Attention Deficit Disorder: A “Review of Reviews”
Swanson, J. M., McBurnett, K., Wigal, T., Pfiffner, L. J., Lerner, M. A., Williams, L., Christian, D. L., Tamm, L., Willcutt, E., Crowley, K., et al. (1993) · Exceptional Children · doi:10.1177/001440299306000209 · Cited by 305 · cited 2×
“of reviews” reported over 3,000 citations and 250 reviews of stimulant treatment (Swanson et al., 1993).”
BackgroundA meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder
CONNOR, D. F., FLETCHER, K. E., & SWANSON, J. M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199912000-00017 · Cited by 297 · cited 1×
“Connor, Fletcher, & Swanson (1999) performed a meta-analysis of 11 studies which suggested clonidine possessed efficacy in the treatment of ADHD, although no definitive studies have been performed.”
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II
PAPPADOPULOS, E., MACINTYRE, J. C., CRISMON, M. L., FINDLING, R. L., MALONE, R. P., DERIVAN, A., SCHOOLER, N., SIKICH, L., GREENHILL, L., SCHUR, S. B., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00008 · Cited by 289
Effect of Stimulants on Height and Weight: A Review of the Literature
Faraone, S. V., Biederman, J., Morley, C. P., & Spencer, T. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.obo13e31817eoea7 · Cited by 286
Volkow, N. D., Wang, G.-J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., Gatley, S. J., Pappas, N., Wong, C., Vaska, P., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1173 · Cited by 281 · cited 1×
“Next, Volkow et al. (2004) examined the effect of MPH on dopamine release in two different situations: while subjects passively viewed pictures and again while performing a difficult mathematics task.”
BackgroundPliszka, S. R., Glahn, D. C., Semrud-Clikeman, M., Franklin, C., Perez III, R., Xiong, J., & Liotti (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.6.1052 · Cited by 278
Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Electrophysiological activity underlying inhibitory control processes in normal adults
Schmajuk, M., Liotti, M., Busse, L., & Woldorff, M. G. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2005.06.005 · Cited by 247
Clinical Utility of EEG in Attention Deficit Hyperactivity Disorder
Loo, S. K., & Barkley, R. A. (2005) · Applied Neuropsychology · doi:10.1207/s15324826an1202_2 · Cited by 241 · cited 4×
“The beta band is associated with mental alertness; most studies have shown that children with ADHD show decreased beta and increased amounts of the other frequencies, particularly in the frontal area (Barry, Clarke, & Johnstone, 2003; Loo & Barkley, 2005 ).”
BackgroundInfluentialElectroencephalogram differences in two subtypes of Attention-Deficit/Hyperactivity Disorder
CLARKE, A. R., BARRY, R. J., McCARTHY, R., & SELIKOWITZ, M. (2001) · Psychophysiology · doi:10.1017/s0048577201981764 · Cited by 240
Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., & Farde, L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.009 · Cited by 236 · cited 1×
“The PET ligand PE2I can also be used to image the dopamine transporter ( Jucaite, Fernell, Halldin, Forssberg, & Farde, 2005 ).”
BackgroundGadow, K. D., Sverd, J., Sprafkin, J., Nolan, E. E., & Grossman, S. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.330 · Cited by 236
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., Winner, P. K., Dunn, D. W., Dure, L. S., Sallee, F. R., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000188869.58300.a7 · Cited by 225 · cited 4×
“should utilize a non-stimulant medication such as atomoxetine (Allen et al., 2005).”
BackgroundInfluentialAman, M. G., Binder, C., & Turgay, A. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649020 · Cited by 203 · cited 1×
“A recent study by Aman et al. (2004) randomized a group of aggressive children with ADHD to risperidone or placebo; one-half of these children were also already being treated with a stimulant for their ADHD and remained on it during the double-blind trial testing risperidone or placebo.”
BackgroundShafritz, K. M., Marchione, K. E., Gore, J. C., Shaywitz, S. E., & Shaywitz, B. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1990 · Cited by 190 · cited 1×
“In a small heterogeneous group of adolescents with ADHD and reading disorders, MPH increased activity in the left ventral basal ganglia relative to placebo, but had no effect on task performance ( Shafritz, Marchione, Gore, Shaywitz, & Shaywitz, 2004 ).”
BackgroundSpencer, T. J., Biederman, J., Madras, B. K., Faraone, S. V., Dougherty, D. D., Bonab, A. A., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.036 · Cited by 185 · cited 6×
“In seven studies reviewed by Spencer et al. (2005), five showed the dopamine transporter binding to be increased in subjects with ADHD relative to controls, while two studies showed no difference between the ADHD and control groups.”
BackgroundMethodResultInfluentialGreenhill, L. L., Findling, R. L., Swanson, J. M., & MPH MR ADHD Study Group (2002) · PEDIATRICS · doi:10.1542/peds.109.3.e39 · Cited by 185
The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder
Krause, K.-H., Dresel, S. H., Krause, J., la Fougere, C., & Ackenheil, M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.08.012 · Cited by 183 · cited 1×
“Krause et al. (2003) obtained SPECT using TRPDAT-1 in a small number of adults with ADHD both at baseline and again after a dose of MPH.”
MethodBiederman, J., Lopez, F. A., Boellner, S. W., & Chandler, M. C. (2002) · Pediatrics · doi:10.1542/peds.110.2.258 · Cited by 180 · cited 1×
“Vles et al. (2003 ) a lso found that dopamine transporter binding potential was reduced after three months of MPH treatment in six boys with ADHD, but the timing of SPECT in relation to the last MPH dose was not reported.”
BackgroundNewcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174
Functional Effects of the DAT1 Polymorphism on EEG Measures in ADHD
LOO, S. K., SPECTER, E., SMOLEN, A., HOPFER, C., TEALE, P. D., & REITE, M. L. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046890.27264.88 · Cited by 169
Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., MacIntyre, J. C., Pappadopulos, E. A., Greenhill, L. L., Schooler, N. R., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00007 · Cited by 168 · cited 1×
“It is prudent to address any psychosocial or parent management problems contributing to the aggression (Pappadopulos et al., 2003; Schur et al., 2003).”
BackgroundGreenhill, L. L., Biederman, J., Boellner, S. W., Rugino, T. A., Sangal, R. B., Earl, C. Q., JIANG, J. G., & Swanson, J. M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205709.63571.c9 · Cited by 160 · cited 1×
“Modafinil Modafinil showed efficacy in the treatment of ADHD in two double-blind, placebo-controlled trials (Greenhill et al., 2006a; Swanson et al., 2006) but the FDA declined to approve it for clinical use.”
BackgroundWilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., Stein, M. A., Conners, C. K., Duby, J., Newcorn, J., et al. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.1.82 · Cited by 160
JENSEN, P. S., YOUNGSTROM, E. A., STEINER, H., FINDLING, R. L., MEYER, R. E., MALONE, R. P., CARLSON, G. A., COCCARO, E. F., AMAN, M. G., BLAIR, J., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31802f1454 · Cited by 159
Weisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., Read, S. C., & Tulloch, S. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900013687 · Cited by 158
Abikoff, H., McGough, J. J., Vitiello, B., McCracken, J. T., Davies, M., Walkup, J. T., Riddle, M. A., Oatis, M. D., Greenhill, L. L., Skrobala, A. M., et al. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000155320.52322.37 · Cited by 149 · cited 1×
“Serotonin reuptake inhibitors are commonly added to stimulants for this subgroup of patients, although data showing the efficacy of this approach are lacking (Abikoff et al., 2005).”
BackgroundEffects of stimulant medications on the EEG of girls with Attention-Deficit/Hyperactivity Disorder
Clarke, A. R., Barry, R. J., McCarthy, R., Selikowitz, M., & Johnstone, S. J. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.08.020 · Cited by 146 · cited 1×
“Clarke et al. (2002) compared 20 children with ADHD who responded well to MPH to 20 children who had responded well to dextroamphetamine using EEG power.”
BackgroundRosa-Neto, P., Lou, H. C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., & Gjedde, A. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.11.031 · Cited by 135 · cited 1×
“Recently, Rosa-Neto et al. (2005) performed a PET raclopride study with nine adolescents with ADHD; the subjects were scanned both on placebo and again on a therapeutic dose of MPH. MPH induced a decrease in raclopride binding relative to placebo.”
BackgroundADHD Treatment With Once-Daily OROS Methylphenidate: Final Results From a Long-Term Open-Label Study
Wilens, T. E., McBurnett, K., Stein, M. A., Lerner, M., Spencer, T. J., & Wolraich, M. L. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000173291.28688.e7 · Cited by 134 · cited 1×
“Many of the short term studies in Table 1 were followed by longer term open label studies lasting 1–2 years (Wilens et al., 2005; McGough et al., 2005).”
BackgroundPLISZKA, S. R., BROWNE, R. G., OLVERA, R. L., & WYNNE, S. K. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200005000-00016 · Cited by 130
Self-citation(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.658 · Cited by 129 · cited 1×
“Cerebral blow flood can be assessed by either SPECT (2001) or PET (Matochik et al., 1993; Matochik et al., 1994) but this technique has not been as fruitful as might be expected, either as a diagnostic tool or to assess stimulant effects in the brain.”
BackgroundGrowth on stimulant medication; clarifying the confusion: a review
Poulton, A. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.056952 · Cited by 129 · cited 2×
“Recently, two major reviews (Poulton, 2005; Faraone, Biederman, Morley, & Spencer, 2006) examined all of the available data and concluded that stimulant treatment may be associated with a reduction in expected height gain, at least in the first 1–3 years of treatment.”
BackgroundDoes Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?
SPENCER, T. J., FARAONE, S. V., BIEDERMAN, J., LERNER, M., COOPER, K. M., & ZIMMERMAN, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205710.01690.d4 · Cited by 125 · cited 1×
“However, two recent 1–3 years follow up studies did not show an impact on growth (Pliszka, Matthews, Braslow, & Watson, 2006c; Spencer et al., 2006a).”
BackgroundWigal, S. B., McGough, J. J., McCracken, J. T., Biederman, J., Spencer, T. J., Posner, K. L., Wigal, T. L., Kollins, S. H., Clark, T. M., Mays, D. A., et al. (2005) · Journal of Attention Disorders · doi:10.1177/1087054705281121 · Cited by 123 · cited 1×
“The algorithm recommends stimulants as the first stage of ADHD treatment due to their large effect size and superiority to non-stimulants in comparative trials (Biederman, Wigal, Spencer, McGough, & Mays, 2006; Wigal et al., 2005).”
Method(2003) · Neuropediatrics · doi:10.1055/s-2003-39602 · Cited by 122 · cited 1×
“Vles et al. (2003) also found that dopamine transporter binding potential was reduced after three months of MPH treatment in six boys with ADHD, but the timing of SPECT in relation to the last MPH dose was not reported.”
BackgroundStimulant Treatment Over 5 Years: Effects on Growth
CHARACH, A., FIGUEROA, M., CHEN, S., ICKOWICZ, A., & SCHACHAR, R. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000199026.91699.20 · Cited by 119 · cited 2×
“Charach et al. (2006) found higher doses of stimulant correlated with reduced gains in height and weight.”
BackgroundSchweitzer, J. B., Lee, D. O., Hanford, R. B., Tagamets, M. A., Hoffman, J. M., Grafton, S. T., & Kilts, C. D. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300110 · Cited by 114 · cited 1×
“MPH induced increases in blood flow in cerebellar vermis, but decreases in precentral gyri, left caudate nucleus, and right claustrum (Schweitzer et al., 2003).”
BackgroundCognitive Event-Related Potentials in Attention Deficit Disorder
Klorman, R. (1991) · Journal of Learning Disabilities · doi:10.1177/002221949102400301 · Cited by 113 · cited 2×
“In most treatment studies of oddball tasks using ERP, MPH enhances the P300 response to the rare stimuli (Klorman, 1991).”
BackgroundClarke, A. R., Barry, R. J., Bond, D., McCarthy, R., & Selikowitz, M. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1205-0 · Cited by 110 · cited 1×
“Clarke et al. (2002) compared 20 children with ADHD who responded well to MPH to 20 children who had responded well to dextroamphetamine using EEG power.”
BackgroundBroyd, S. J., Johnstone, S. J., Barry, R. J., Clarke, A. R., McCarthy, R., Selikowitz, M., & Lawrence, C. A. (2005) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2005.03.008 · Cited by 106 · cited 1×
“When on MPH, the N200 to No Go stimuli of children with ADHD no longer showed any differences from controls (Broyd et al., 2005).”
BackgroundPLISZKA, S. R., MATTHEWS, T. L., BRASLOW, K. J., & WATSON, M. A. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205702.48324.fd · Cited by 106 · cited 5×
“Medication algorithm for ADHD The Texas Children’s Medication Algorithm Project (CMAP) has recently updated its guidelines for ADHD treatment (Pliszka et al., 2006a).”
BackgroundMethodInfluentialSelf-citationEffects of Acute Stimulant Medication on Cerebral Metabolism in Adults with Hyperactivity
Matochik, J. A., Nordahl, T. E., Gross, M., Semple, W. E., King, A. C., Cohen, R. M., & Zametkin, A. J. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.38 · Cited by 105 · cited 9×
“Reviewing these data, Castellanos (2002) questioned the utility of SPECT/PET cerebral blood flow studies, suggesting that fMRI and assessment of catecholamine transporter would be more likely to lead to further understanding of the mechanisms of pharmacological treatments for ADHD.”
BackgroundInfluentialJONKMAN, L. M., KEMNER, C., VERBATEN, M. N., VAN ENGELAND, H., CAMFFERMAN, G., BUITELAAR, J. K., & KOELEGA, H. S. (2000) · Psychophysiology · doi:10.1017/s0048577200980867 · Cited by 105 · cited 1×
“Jonkman et al. (2000) obtained ERP on healthy controls and children with ADHD while they performed a decision task, which was presented in both easy and hard conditions.”
MethodSwanson, J. M., Greenhill, L. L., Lopez, F. A., Sedillo, A., Earl, C. Q., Jiang, J. G., & Biederman, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0120 · Cited by 103 · cited 2×
“Modafinil Modafinil showed efficacy in the treatment of ADHD in two double-blind, placebo-controlled trials (Greenhill et al., 2006a; Swanson et al., 2006) but the FDA declined to approve it for clinical use.”
BackgroundSpencer, T. J., Wilens, T. E., Biederman, J., Weisler, R. H., Read, S. C., & Pratt, R. D. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.02.011 · Cited by 102 · cited 1×
“MSA Adderall XR 278 adolescents aged 4 weeks, DBPC parallel Response rates: Placebo- 27% Decreased appetite- 36% ( Spencer et al., 2006b ) 10–17 years groups 10 mg-52% Headache-16% 20 mg 66% Weight loss-9% 30 mg 71% Insomnia-12; 40 mg 64%”
BackgroundConnor, D. F., Boone, R. T., Steingard, R. J., Lopez, I. D., & Melloni, R. H. (2003) · Journal of Emotional and Behavioral Disorders · doi:10.1177/10634266030110030301 · Cited by 99
McGough, J. J., Biederman, J., Wigal, S. B., López, F. A., McCracken, J. T., Spencer, T. J., Zhang, Y., & Tulloch, S. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157550.94702.a2 · Cited by 95 · cited 1×
“Many of the short term studies in Table 1 were followed by longer term open label studies lasting 1–2 years (Wilens et al., 2005; McGough et al., 2005).”
BackgroundClarke, A. R., Barry, R. J., McCarthy, R., & Selikowitz, M. (2002) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00736-2 · Cited by 92 · cited 1×
“Clarke et al. (2002) compared 20 children with ADHD who responded well to MPH to 20 children who had responded well to dextroamphetamine using EEG power.”
BackgroundKim, B. N., Lee, J. S., Cho, S. C., & Lee, D. S. (2001) · Yonsei Medical Journal · doi:10.3349/ymj.2001.42.1.19 · Cited by 88 · cited 2×
“This would also suggest that stimulants might act by increasing cortical arousal, consistent with the blood flow studies of Kim et al. (2001) noted above.”
BackgroundResultShort- and Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Children
Findling, R. L., Biederman, J., Wilens, T. E., Spencer, T. J., McGough, J. J., López, F. A., & Tulloch, S. J. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.03.014 · Cited by 86 · cited 1×
“No serious adverse events were reported and laboratory and electrocardiogram (ECG) findings were unremarkable (Findling et al., 2005).”
BackgroundLong-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD
Biederman, J., Spencer, T. J., Wilens, T. E., Weisler, R. H., Read, S. C., & Tulloch, S. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900002406 · Cited by 79 · cited 1×
“The use of amphetamine in children with disruptive behavior disorders was first described by Bradley (1937) seven decades ago, thus the treatment of ADHD (albeit referred to by many different names) predates the use of antibiotics.”
BackgroundAripiprazole in the Treatment of Pediatric Bipolar Disorder: A Systematic Chart Review
Biederman, J., McDonnell, M. A., Wozniak, J., Spencer, T., Aleardi, M., Falzone, R., & Mick, E. (2005) · CNS Spectrums · doi:10.1017/s1092852900019489 · Cited by 75
Seifert, J., Scheuerpflug, P., Zillessen, K. E., Fallgatter, A. J., & Warnke, A. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0818-8 · Cited by 73 · cited 1×
“Seventeen boys with ADHD performed the CPT while ERP was obtained at baseline and then one week later after a 10 mg dose of MPH ( Seifert, Scheuerpflug, Zillessen, Fallgatter, & Warnke, 2003 ).”
MethodLoo, S. K., Hopfer, C., Teale, P. D., & Reite, M. L. (2004) · Journal of Clinical Neurophysiology · doi:10.1097/01.wnp.0000150890.14421.9a · Cited by 73 · cited 2×
“Loo et al. (2004) , found similar results, adding that MPH non responders tended to show decreased beta while on medication.”
ResultLack of effects of guanfacine on executive and memory functions in healthy male volunteers
Müller, U., Clark, L., Lam, M. L., Moore, R. M., Murphy, C. L., Richmond, N. K., Sandhu, R. S., Wilkins, I. A., Menon, D. K., Sahakian, B. J., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0078-4 · Cited by 73
Greenhill, L. L., Muniz, R., BALL, R. R., Levine, A. J., Pestreich, L. K., & Jiang, H. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220847.41027.5d · Cited by 70 · cited 1×
“d-MPH Focalin XR 97 children aged 6–17 7 week, DBPC parallel Response rates: d-MPH-67% ( Greenhill et al., 2006b ) years groups Placebo-13%”
BackgroundTHE USE OF TRICYCLIC ANTIDEPRESSANTS IN CHILDREN AND ADOLESCENTS
Daly, J. M., & Wilens, T. E. (1998) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70065-1 · Cited by 64 · cited 2×
“Controlled studies have shown that tricyclic antidepressants are superior to placebo in ADHD treatment, although the effect size is less than that of stimulants ( Daly & Wilens, 1998 ).”
BackgroundLangleben, D. D., Acton, P. D., Austin, G., Elman, I., Krikorian, G., Monterosso, J. R., Portnoy, O., Ridlehuber, H. W., & Strausś, H. W. (2002) · PubMed · Cited by 62
Szobot, C. M., Ketzer, C. R., Cunha, R. D., Parente, M. A. D. M. P., Langleben, D. D., Acton, P. D., Kapczinski, F. P., & Rohde, L. A. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1082-0 · Cited by 40 · cited 2×
“adolescents, and adults (Michelson et al., 2003; Michelson et al., 2001; Michelson et al., 2002; Swensen, Michelsen, Buesching, & Faries, 2001 ).”
BackgroundFERON, F. J. M., Hendriksen, J. G. M., van Kroonenburgh, M. J. P. G., Blom-Coenjaerts, C., Kessels, A. G. H., Jolles, J., Weber, W. E. J., & Vles, J. S. H. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.04.008 · Cited by 40 · cited 2×
“suggesting that MPH does not induce any long term down regulation of the transporter (Feron et al., 2005).”
BackgroundCastellanos, F. X. (2002) · PubMed · Cited by 39
Attention Deficit Hyperactivity Disorder
Swanson, J. M., Volkow, N. D., Newcorn, J. H., Casey, B. J., Moyzis, R. K., Grandy, D. K., & Posner, M. I. (2006) · Wiley eBooks · doi:10.1002/0470018860.s00416 · Cited by 38
Biederman, J., Wigal, S. B., Spencer, T. J., McGough, J. J., & Mays, D. A. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.02.008 · Cited by 34 · cited 2×
“OROS-MPH Concerta 141 adults 6 weeks, DBPC parallel groups 66% response to MPH, 39% to placebo Small but clinically insignificant effects on blood pressure ( Biederman et al., 2006 )”
BackgroundMethodWeiss, M. D., Wasdell, M. B., & Patin, J. R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000138352.06229.b0 · Cited by 22 · cited 1×
“MPH has both a dextro (d) and levo (l) isomer; the d-MPH isomer alone shows efficacy equal to that of the d, 1-MPH form, with some evidence that the d-isomer administered alone has a slightly longer duration of action than d,l.-MPH ( Weiss, Wasdell, & Patin, 2004 ).”
BackgroundSchur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., MacIntyre, J. C., Pappadopulos, E. A., Greenhill, L. L., Schooler, N. R., et al. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.4.596 · Cited by 21
ATOMOXETINE TREATMENT FOR PEDIATRIC PATIENTS WITH ADHD AND COMORBID ANXIETY
Sumner, C., Sher, L., Sutton, V, Bakken, R., Paczkowski, M., Trzepacz, P., & Kelsey, D. (2006) · Neuropediatrics · doi:10.1055/s-2006-945667 · Cited by 19
Cited by
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 671
“Moreover, current pharmacologic treatments for ADHD (e.g., methylphenidate) target dopaminergic systems, and, similar to MA, operate by blocking reuptake of dopamine and norepinephrine (Pliszka 2007).”
BackgroundSharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
“Comorbidities such as ODD, MDD, and anxiety disorders create more difficulties for ADHD diagnosis because of the similarities of these disorders with symptoms and characteristics of ADHD.”
BackgroundInfluentialA Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
“Although different pharmacological treatment strategies have been applied to ADHD patients with various comorbidities, evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerabilit…”
BackgroundAttention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358
“Pliszka SR (2007). Pharmacologic treatment of attention-deficit/hyperactivity”
BackgroundInfluentialAdvokat, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.006 · Cited by 219
Metadata
- Authors
- Pliszka, S. R.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Pliszka, Steven R.
- ORCID
- Pliszka, Steven R.
- Venue
- Neuropsychology Review
- Published
- 2007-01-23
- Volume
- 17
- Issue
- 1
- Pages
- 61-72
- ISSN
- 1040-7308 (ISSN-L)
- 1573-6660
- OpenAlex
- W2081088104
- Cited by
- 158
- References
- 99
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 3 · 2020: 10 · 2019: 11 · 2018: 2 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 12 · 2013: 5 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychology Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- attention deficit hyperactivity disorder, pharmacotherapy, long-acting stimulants, atomoxetine, drug efficacy, drug safety, adverse effects, sudden death risk, mechanism of action, catecholamines, prefrontal cortex, anterior cingulate cortex, neuroimaging
- MeSH terms
- Atomoxetine Hydrochloride, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Decision Trees, Humans, Propylamines, Neurotransmitter Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.